Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Viatris Inc (VTRS)

15.22   0.2 (1.33%) 01-16 05:18
Open: 14.902 Pre. Close: 15.02
High: 15.255 Low: 14.8604
Volume: 5,773,965 Market Cap: 18,407M
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.268 - 15.343 15.343 - 15.419
Low: 14.684 - 14.761 14.761 - 14.84
Close: 15.094 - 15.218 15.218 - 15.344

Technical analysis

as of: 2022-01-15 8:50:44 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 17.92     One year: 20.93
Support: Support1: 13.52    Support2: 12.40
Resistance: Resistance1: 15.34    Resistance2: 17.92
Pivot: 14.40
Moving Average: MA(5): 15.15     MA(20): 14.09
MA(100): 13.65     MA(250): 14.38
MACD: MACD(12,26): 0.56     Signal(9): 0.43
Stochastic oscillator: %K(14,3): 90.27     %D(3): 93.24
RSI: RSI(14): 74.48
52-week: High: 18.68  Low: 11.96  Change(%): -12.1
Average Vol(K): 3-Month: 1044296  10-Days: 1003908

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
VTRS has closed below upper band by 18.3%. Bollinger Bands are 77.7% wider than normal. The large width of the bands suggest high volatility as compared to VTRS's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue.

Headline News

Tue, 11 Jan 2022
Viatris: Prepare For Takeoff - Seeking Alpha

Thu, 06 Jan 2022
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend - Yahoo Finance

Tue, 04 Jan 2022
TWTR: 4 Stocks in the S&P 500 Wall Street Predicts Will Rally by More Than 20% in 2022 -

Mon, 03 Jan 2022
Bullish Two Hundred Day Moving Average Cross - VTRS - Nasdaq

Wed, 29 Dec 2021
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations - Yahoo Finance

Thu, 23 Dec 2021
Interesting VTRS Put And Call Options For February 2022 - Nasdaq

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. (M) 1,210
Shares Float (M) 1,210
% Held by Insiders 0.25
% Held by Institutions 75.18
Shares Short (K) 24,810
Shares Short P. Month (K) 28,450

Stock Financials

EPS -1.720
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 17.480
Profit Margin -11.19
Operating Margin 13.26
Return on Assets (ttm) 3.3
Return on Equity (ttm) -11.4
Qtrly Rev. Growth 52.6
Gross Profit (p.s.) 3.950
Sales Per Share 14.190
EBITDA (p.s.) 5.504
Qtrly Earnings Growth 67.70
Operating Cash Flow (M) 2,530
Levered Free Cash Flow (M) 3,320

Stock Valuations

PE Ratio -8.85
PEG Ratio
Price to Book value 0.87
Price to Sales 1.07
Price to Cash Flow 7.28

Stock Dividends

Dividend 0.330
Forward Dividend 0.440
Dividend Yield 0.02
Dividend Pay Date 2021-12-15
Ex-Dividend Date 2021-11-21
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.